Gaming and Abuse of Orphan Drugs

Pattern of gaming the system by slicing and dicing indications so that drugs qualify for lucrative orphan status benefits and getting taxpayer subsidies for blockbuster drugs, says a veteran scientist in USA. Companies are intentionally exploiting the law by putting up an initial listing of only single narrow indication for an orphan drugs use, which is just enough to qualify for "orphan" drug designation. Under the terms of this act, companies can receive federal taxpayer subsidies of up to half a million dollars a year for up to four years per drug, large tax credits and waivers of marketing application fees that can cost more than $2 million. In addition, the Food and Drug Administration (FDA) can grant companies seven years of marketing exclusivity for an orphan drug to ensure they recoup the costs of research and development. When those financial incentives become sort of an investment opportunity to take advantage of the Orphan Drug Act. The review found that orphan drug spending in the United States totalled $15 billion in 2007 and $30 billion in 2013, an increase from 4.8 percent of total pharmaceutical spending to 8.9 percent. The current study projects orphan drug spending will remain fairly stable as a proportion of total drug spending. That stands in contrast to other published reports that estimate orphan drugs will account for 20 percent of worldwide spending on drugs (other than generics) by 2020.

Pattern of gaming the system by slicing and dicing indications so that drugs qualify for lucrative orphan status benefits and getting taxpayer subsidies for blockbuster drugs, says a veteran scientist in USA. Companies are intentionally exploiting the law by putting up an initial listing of only single narrow indication for an orphan drugs use, which is just enough to qualify for "orphan" drug designation. Under the terms of this act, companies can receive federal taxpayer subsidies of up to half a million dollars a year for up to four years per drug, large tax credits and waivers of marketing application fees that can cost more than $2 million. In addition, the Food and Drug Administration (FDA) can grant companies seven years of marketing exclusivity for an orphan drug to ensure they recoup the costs of research and development. When those financial incentives become sort of an investment opportunity to take advantage of the Orphan Drug Act. The review found that orphan drug spending in the United States totalled $15 billion in 2007 and $30 billion in 2013, an increase from 4.8 percent of total pharmaceutical spending to 8.9 percent. The current study projects orphan drug spending will remain fairly stable as a proportion of total drug spending. That stands in contrast to other published reports that estimate orphan drugs will account for 20 percent of worldwide spending on drugs (other than generics) by 2020.

  • Financial incentives
  • Recouping the costs of research and development for orphan drugs
  • Forecasts of amount to be spent on orphan drugs by 2020

Related Conference of Gaming and Abuse of Orphan Drugs

March 19-20, 2018

International Meeting on Nutraceuticals

Singapore
March 26-27, 2018

World Congress on Herbal and Chinese Medicine

Bali, Indonesia
April 20-21, 2018

4th International Conference on Antibiotics: R&D, B2B

Las Vegas, Nevada, USA
April 26-27, 2018

11th European Biosimilars Congress

Rome, Italy
May 07-09, 2018

15th Annual European Pharma Congress

Frankfurt, Germany
June 18-20, 2018

International Conference on Pharmacology

Tokyo, Japan
June 18-20, 2018

International Conference on Pharmacology

Tokyo, Japan
June 20-22, 2018

7th World Congress on Mass Spectrometry

Rome, Italy
June 27-28, 2018

International Conference on Pharmaceutical Analysis and Quality Control Strategies

Vancouver, British Columbia, Canada
July 16-17, 2018

12th Global
Pharmacovigilance & Clinical Trials Summit

Sydney, Australia
July 18-20, 2018

15th Asia-Pacific Pharma Congress

Melbourne, Australia
Jul 30-Aug 01, 2018

10th World Congress on Pharmacology

Barcelona, Spain
July 31-August 01, 2017

Analytical and Bio-Analytical Techniques Congress

Melbourne, Australia
August 15-17, 2018

14th World Congress on Pharmacology and Drug Safety

Stockholm, Sweden
August 20-21, 2018

World Biosimilars Conference

Chicago, USA
September 03-05, 2018

International Conference onClinical Pharmacy

Zurich, Switzerland
September 13-14, 2018

8th World Congress on Chromatography

Prague, Czech Republic
September 14-15, 2018

Annual Neurochemistry and Neuropharmacology Congress

Richmond, Virginia, USA
September 17-18, 2018

5th International Conference on Clinical Pharmacy and Pharmacy Practice

San Antonio, Texas, USA
September 17-18, 2018 | San Antonio, Texas, USA

11th World Congress on Pharmacology & Therapeutics

September 17-18, 2018

Annual Pharmacy and Pharmaceutical Science Conference

Kuala Lumpur, Malaysia
September 17-18, 2018

15th International Conference on Pharmaceutical Formulations & Drug Delivery

| Philadelphia, Pennsylvania, USA
September 17-18, 2018

Drug formulation Congress 2018

Singapore
September 20-22, 2018

17th Annual Congress on Pharmaceutics & Drug Delivery Systems

Prague, Czech Republic
September 24-26, 2018

7th International Conference on Clinical Trials

| Chicago, Illinois, USA
(10 Plenary Forums - 1 Event)
September 24-26, 2018

International Conference on Case Reports

Toronto, Canada
September 24-25, 2018

Pharmacoepidemiology 2018

Dubai, UAE
September 26-27, 2018

Annual Pharma Pricing & Marketing Congress

Dubai, UAE
September 28-29, 2018

11th World Congress on Pharmaceutical Sciences

| Montreal, Canada
October 01-03, 2018

Global Medicinal Chemistry & GPCR Summit

Las Vegas, USA
September 24-25, 2018

12th World Drug Delivery Summit

(10 Plenary Forums - 1Event)
Chicago, Illinois, USA
October 22-23, 2018

18th Annual Pharma Middle East Congress

Abu Dhabi, UAE
August 24-25, 2018

7th Global Advances in Mass Spectrometry

Singapore
October 24-25, 2018

13th International Conference on Biopharma and Biotherapeutics

Boston, Massachusetts, USA
Oct 31- Nov 01, 2018

34th International Conference on Pharmaceuticals & Nutraceuticals

San Francisco, California, USA
November 15-16, 2018

9th Global Experts Meeting on Neuropharmacology

Frankfurt, Germany

Gaming and Abuse of Orphan Drugs Conference Speakers